JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage
diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier
this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had
been appointed as the interim Chief Executive Officer recently in March.
Heino von Prondzynski the Chairman of Quotient’s board of directors commented, “I have had the pleasure of
working with and observing Franz’s career as he took on a variety of ever increasing responsibilities during the last 20 years. I
speak for the whole board in saying we are confident that Franz brings a skill set and experiences that match very well with the
needs of Quotient in this next stage of its development.”
Franz Walt added, “When I joined the board of Quotient earlier this year, I was inspired by the Company’s vision
of microarray technology taking a leading position in the field of diagnostic screening. Having engaged with the team and learned
more about the capabilities of MosaiQ I am more enthusiastic than ever about the potential of MosaiQ as a transformational
platform. While taking this responsibility was not my original plan when I joined the board I am very excited about the potential
to make a positive contribution to the introduction of such a ground breaking diagnostic technology.”
Mr Walt has 30 years' experience in leadership roles at two of the largest and most influential global
healthcare companies, Siemens Healthineers and Roche. As President, Laboratory Diagnostics at Siemens Healthineers, Franz was
responsible for the recent global launch of Siemens’ next generation laboratory diagnostics platform, the Atellica Solution. Franz
Walt said, “Quotient has a high quality team that I have enjoyed getting to know over the last two months. I am looking forward to
working with them to provide support and direction as MosaiQ advances.”
MosaiQ Platform
MosaiQ, Quotient's next-generation platform is designed to deliver fast, comprehensive antigen typing, antibody
detection and disease screening results, using a single low volume sample in a high throughput automated format. MosaiQ represents
a transformative and highly disruptive unified testing platform for transfusion diagnostics. Feasibility has also been demonstrated
with respect to the detection of nucleic acids (DNA or RNA) using the MosaiQ platform. Through MosaiQ, Quotient expects to deliver
substantial value to donor testing laboratories worldwide by providing affordable, routine comprehensive characterization and
screening of blood products, on a single automated instrument platform designed to radically reduce labor costs and complexity
associated with existing practice.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient
care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological
disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that
is unmatched by existing commercially available transfusion diagnostic instrument platforms. The Company’s operations are based in
Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include statements regarding our expectations relating to our management team and the development,
regulatory approval, commercialization and impact of MosaiQ. Such statements are based on current assumptions that involve
risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of
which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market
acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development,
clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing,
product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or
worsening adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the
Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these
forward-looking statements.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer – chris.lindop@quotientbd.com; +41 22 545 52 26